-
Biocytogen’s First-in-Class B7H3/PTK7 Bispecific ADC Option Exercised by IDEAYA Biosciences
•
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315), a China-based biopharmaceutical company, has announced that its US partner IDEAYA Biosciences Inc. (NASDAQ: IDYA) has exercised its option for an exclusive worldwide license for Biocytogen’s IDE034. This potential first-in-class B7H3/PTK7 topo-I-payload bispecific antibody drug conjugate (BsADC) represents a significant step forward in…
-
Biocytogen Strikes Licensing Deal with IDEAYA for Potential First-in-Class BsADC Program
•
China-based Biocytogen (HKG: 2315) has entered into an option and licensing agreement with US-based IDEAYA Biosciences Inc. (NASDAQ: IDYA) for the development of Biocytogen’s B7H3/PTK7 program, a potential first-in-class bispecific antibody drug conjugate (BsADC). The agreement grants IDEAYA the option for an exclusive worldwide license to the drug, which has…
-
Biocytogen Strikes Exclusive Deal with SOTIO Biotech for Next-Gen ADCs
•
Biocytogen (HKG: 2315), a leading biopharmaceutical company based in China, has announced a strategic research collaboration and licensing agreement with the Netherlands-based SOTIO Biotech B.V. The partnership grants SOTIO an exclusive option to license multiple fully human bispecific antibodies generated through Biocytogen’s proprietary RenLite platform. These antibodies will be utilized…
-
Biocytogen Secures US Patent for RenLite Fully Human Common Light Chain Mouse Platform
•
Biocytogen (HKG: 2315), a biopharmaceutical company based in China, has announced that it has been granted a patent by the United States Patent and Trademark Office (USPTO) for its independently developed RenLite fully human common light chain mouse platform. The RenLite mice, developed utilizing Biocytogen’s proprietary Size-Unlimited and Precise Chromosome…
-
Biocytogen Expands Reach to India with GVSAP Partnership for BioMice Models
•
A recent stock exchange announcement from China-based Biocytogen (HKG: 2315) has highlighted a strategic partnership with GV Safety Assessment Platform (GVSAP), a preclinical Contract Research Organization (CRO) and subsidiary of GV Research Platform (GVRP) in India. This new collaboration will provide Indian researchers with access to Biocytogen’s innovative BioMice models…
-
Biocytogen and BioCopy AG Collaborate on TCR-Mimic Antibody Development for Cancer Therapies
•
Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315), a China-based biopharmaceutical company, has announced an evaluation and potential licensing agreement with BioCopy AG, a research-driven biotechnology firm based in Basel, Switzerland. This agreement grants BioCopy access to a fully human library of TCR-mimic antibodies that target intracellular antigens. These antibodies are…
-
Biocytogen and ABL Bio Forge Partnership to Advance Bispecific ADC Development
•
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) has entered into a partnership with South Korea’s ABL Bio Inc. (KOSDAQ: 298380) to advance the development of bispecific antibody drug conjugates (ADCs). ABL Bio is a research-driven biotechnology firm recognized for its pioneering work in bispecific antibodies aimed at treating immuno-oncology…
-
Biocytogen Pharmaceuticals Inks Antibody Evaluation Deal with Gilead Sciences
•
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315), a China-based biopharmaceutical company, has announced an antibody evaluation and option agreement with Gilead Sciences, Inc. This deal grants the US pharmaceutical major access to Biocytogen’s comprehensive fully human antibody library, which has been developed against a broad spectrum of therapeutic targets. Over…
-
Manhattan BioSolutions Strikes Agreement with Biocytogen for Access to Novel Tumor Antigens
•
Manhattan BioSolutions Inc., a U.S.-based biotechnology company, has entered into an assessment and potential licensing agreement with Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315), a Chinese biopharmaceutical firm. Through this agreement, Manhattan BioSolutions is poised to gain access to a range of antibodies targeting a novel tumor antigen that is…
-
Biocytogen Launches RenBiologics Sub-brand to Expand Antibody Discovery Business
•
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315), a China-based biopharmaceutical company, has announced the launch of a new sub-brand, RenBiologics, to represent its antibody discovery business division. The RenBiologics business will focus on out-licensing and co-development of the company’s extensive library of fully human antibodies, as well as licensing of…
-
Biocytogen Strikes Exclusive Licensing Deal with US-Based Radiance Biopharma for Innovative BsADC
•
Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315), a leading biopharmaceutical company based in China , has announced the signing of an Exclusive Option and License Agreement with Radiance Biopharma Inc., a specialist in antibody drug conjugates (ADCs) headquartered in Boston, U.S. The agreement provides Radiance with the option to license…
-
Biocytogen and Lepu Biotechnology Develop WT1-Targeted Trispecific Antibody for Cancer Treatment
•
Biocytogen Pharmaceuticals (Beijing) Co., Ltd, (HKG: 2315) and Lepu Biotechnology Co., Ltd (HKG: 2157) have announced significant progress in the co-development of their trispecific T cell connector, having identified a WT1/HLA-A02 targeted T-cell connector, WT1×CD3×4-1BB trispecific antibody, as part of their collaboration initiated last year. Pre-clinical data for this product…
-
Biocytogen Pharmaceuticals Inks Antibody Deal with Neurocrine Biosciences
•
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd, (HKG: 2315) has announced an antibody assessment and option agreement with US firm Neurocrine Biosciences Inc. The agreement grants Neurocrine access to Biocytogen’s fully human antibodies targeting multiple specified therapeutic areas, with an option to license selected antibodies for global development, manufacturing, and commercialization.…
-
Biocytogen and Ona Therapeutics Forge Antibody Evaluation and Licensing Agreement
•
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315), based in China, has entered into an antibody evaluation, option, and licensing agreement with Spain’s Ona Therapeutics. According to the terms of the agreement, Biocytogen will provide Ona with access to evaluate its proprietary RenMice-derived fully human antibodies targeting a specific tumor. Ona…
-
Biocytogen Pharmaceuticals Secures US Patent for Fully Human Antibody Mice Platform RenMab
•
Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315), a China-based Contract Research Organization (CRO), has announced the receipt of patent approval in the United States for its proprietary core technology, the fully human antibody mice platform RenMab. This U.S. patent award comes on the heels of a similar award in China…
